A Phase 1/2 interventional study of Nivolumab and Ipilimumab in Solid Tumor, sponsored by Bristol-Myers Squibb. Completed at 12 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to evaluate the safety and effectiveness of Nivolumab in combination with Ipilimumab in Chinese participants with previously treated late stage cancer.
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Nivolumab · Drug: Ipilimumab
Drug: Nivolumab · Drug: Ipilimumab
Drug: Nivolumab · Drug: Ipilimumab
Drug: Nivolumab · Drug: Ipilimumab
Specified dose on specified days
Also known as: BMS-936558, Opdivo
Specified dose on specified days
Also known as: BMS-734016, Yervoy
Number of Participants With Adverse Events (AEs) in Part 1.
Number of participants with Adverse events
Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Number of Participants With Serious Adverse Events (SAEs) in Part 1.
Number of participants with Adverse events
Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Number of Participants With Adverse Events Leading to Discontinuation in Part 1.
Number of participants with Adverse events
Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Number of Participants With Adverse Events Leading to Death in Part 1.
Number of participants with Adverse Events leading to death.
Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
Number of Participants With Clinical Laboratory Abnormalities in Part 1.
Number of participants with clinical laboratory abnormalities.
Time frame: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months)
BICR-Assessed ORR in Part 2
ORR is defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by BICR, according to RECIST v1.1 criteria, divided by the number of treated subjects. The BOR is defined as the best response designation recorded between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. For purposes of analysis, if a subject receives one dose and discontinues the study without assessment or receives subsequent therapy prior to assessment, this participant will be counted in the denominator (as nonrespondent).
Time frame: between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first as assessed by BICR. (Approximately on average 3.21 Months)
Cmax - Maximum Observed Serum Concentration in Part 1.
Cmax - Maximum observed serum concentration in Part 1.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Tmax - Time of Maximum Observed Serum Concentration in Part 1.
Tmax - Time of maximum observed serum concentration in Part 1.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
AUC(0-T) - Area Under the Plasma Concentration-time Curve in Part 1.
AUC(0-T) - Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration. in Part 1.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
AUC(TAU) - Area Under the Concentration-time Curve in One Dosing Interval in Part 1.
AUC(TAU) - Area under the concentration-time curve in one dosing interval in Part 1.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Ceoinf - Serum Concentration Achieved at the End of Study Drug Infusion in Part 1.
Ceoinf - Serum concentration achieved at the end of study drug infusion in Part 1.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Ctau - Concentration at the End of Dosing Interval in Part 1.
Ctau - Concentration at the end of dosing interval in Part 1. The Ctau is equivilant to the CTrough at these time points.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
CLT - Total Body Clearance in Part 1.
CLT - Total body clearance in Part 1.
Time frame: At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Css-avg - Average Concentration Over a Dosing Interval (AUC(TAU)/Tau) in Part 1.
Css-avg - Average concentration over a dosing interval (AUC(TAU)/tau) in Part 1.
Time frame: At Cycle 1 Day 1 and Cycle 3 Day 1 for Arm A, Cycle 1 and Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
AI - Accumulation Index in Part 1.
AI - Accumulation index; ratio of an exposure measure at steady-state to that after the first dose (exposure measure includes AUC (TAU) in Part 1. Here SS = Steady State Here FD = First Dose
Time frame: At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
T-HALFeff - Effective Elimination Half-life in Part 1.
T-HALFeff - Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC(TAU), Cmax, or Ctau) in Part 1.
Time frame: At Cycle 3 Day 1 for Arm A, Cycle 2 Day 1 for Arm B and C (1 cycle = 42 days)
Number of Participants With Nivolumab Anti Drug Antibodies in Part 1.
Number of participants with nivolumab Anti Drug Antibodies in Part 1.
Time frame: At baseline and from first dose to last dose (Approximately on average of Arm A 24.54 weeks, Arm B 76 weeks, Arm C 92.5 Weeks)
Number of Participants With Ipilimumab Anti Drug Antibodies in Part 1.
Number of participants with Ipilimumab Anti Drug Antibodies in Part 1.
Time frame: At baseline and from first dose to last dose (Approximately on average of Arm A 24.54 weeks, Arm B 76 weeks, Arm C 92.5 Weeks)
Investigator-Assessed ORR in Part 2
ORR is defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by Investigator, according to RECIST v1.1 criteria, divided by the number of treated subjects. The BOR is defined as the best response designation recorded between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. For purposes of analysis, if a subject receives one dose and discontinues the study without assessment or receives subsequent therapy prior to assessment, this participant will be counted in the denominator (as nonrespondent).
Time frame: between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first as assessed by the Investigator. (Approximately on average 2 Months)
Investigator-Assessed Disease Control Rate (DCR) in Part 2
The percentage of participants whose BOR is confirmed CR or confirmed PR or stable disease (SD) for at least 12 weeks as per investigator.
Time frame: between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 as assessed by the Investigator. (Approximately on average 5 Months)
BICR-Assessed Disease Control Rate (DCR) in Part 2
The percentage of participants whose BOR is confirmed CR or confirmed PR or stable disease (SD) for at least 12 weeks as per BICR.
Time frame: Approximately 5.92 Months
BICR-Assessed Duration of Response (DOR) in Part 2
The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per BICR.
Time frame: From first dose to 100 days post last dose (approximately 102 weeks)
Investigator-Assessed Duration of Response (DOR) in Part 2
The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per investigator.
Time frame: From first dose to 100 days post last dose (approximately 102 weeks)
BICR-Assessed Progression Free Survival (PFS) in Part 2
The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per BICR.
Time frame: From first dose to 100 days post last dose (approximately 102 weeks)
Investigator-Assessed Progression Free Survival (PFS) in Part 2
The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per investigator.
Time frame: From first dose to 100 days post last dose (approximately 102 weeks)
| Milestone | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C | Part 2: Arm D |
|---|---|---|---|---|
| Started | 9 | 9 | 9 | 9 |
| Completed | 1 | 4 | 1 | 7 |
| Not completed | 8 | 5 | 8 | 2 |
| Withdrew: Disease progression | 5 | 4 | 6 | 1 |
| Withdrew: Study drug toxicity | 2 | 0 | 0 | 1 |
| Withdrew: Participant requested to discontinue study treatment | 0 | 1 | 0 | 0 |
| Withdrew: Participant withdrew consent | 1 | 0 | 0 | 0 |
| Withdrew: Maximum clinical benefit | 0 | 0 | 1 | 0 |
| Withdrew: Other reasons | 0 | 0 | 1 | 0 |
Number of participants with Adverse events
| Participants | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Number of Participants With Adverse Events (AEs) in Part 1. | 7 | 9 | 9 |
Number of participants with Adverse events
| Participants | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Number of Participants With Serious Adverse Events (SAEs) in Part 1. | 4 | 3 | 3 |
Number of participants with Adverse events
| Participants | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Number of Participants With Adverse Events Leading to Discontinuation in Part 1. | 3 | 0 | 0 |
Number of participants with Adverse Events leading to death.
| Participants | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Number of Participants With Adverse Events Leading to Death in Part 1. | 1 | 1 | 0 |
Number of participants with clinical laboratory abnormalities.
| Participants | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Any Grade | 5 | 9 | 7 |
| Grade 3-4 | 1 | 4 | 1 |
ORR is defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by BICR, according to RECIST v1.1 criteria, divided by the number of treated subjects. The BOR is defined as the best response designation recorded between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. For purposes of analysis, if a subject receives one dose and discontinues the study without assessment or receives subsequent therapy prior to assessment, this participant will be counted in the denominator (as nonrespondent).
| Percentage of Participants | Part 2: Arm D |
|---|---|
| BICR-Assessed ORR in Part 2 | 77.8 (40.0 to 97.2) |
Cmax - Maximum observed serum concentration in Part 1.
| ug/mL | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 1 | 59.7 ± 19 | 69.5 ± 19 | 22.5 ± 14 |
| Nivo Cycle 2 | — | 104 ± 12 | 27.2 ± 21 |
| Nivo Cycle 3 | 122 ± 21 | — | — |
| Ipi Cycle 1 | 18.9 ± 18 | 16.8 ± 43 | 55.0 ± 33 |
| Ipi Cycle 2 | — | 22.0 ± 16 | 64.1 ± 29 |
| Ipi Cycle 3 | 20.1 ± 17 | — | — |
Tmax - Time of maximum observed serum concentration in Part 1.
| Hours | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 1 | 1.68 (1.6 to 8.0) | 1.62 (1.5 to 48.0) | 1.59 (1.5 to 1.6) |
| Nivo Cycle 2 | — | 1.55 (1.5 to 47.9) | 4.78 (1.6 to 8.0) |
| Nivo Cycle 3 | 1.65 (1.6 to 8.0) | — | — |
| Ipi Cycle 1 | 0.617 (0.5 to 7.0) | 6.83 (0.5 to 46.9) | 0.517 (0.5 to 6.8) |
| Ipi Cycle 2 | — | 6.98 (0.5 to 7.0) | 0.542 (0.5 to 6.9) |
| Ipi Cycle 3 | 6.78 (0.5 to 6.9) | — | — |
AUC(0-T) - Area under the plasma concentration-time curve from time zero to the last time of the last quantifiable concentration. in Part 1.
| h*ug/mL | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 1 | 10329 ± 21 | 14141 ± 26 | 4056 ± 25 |
| Nivo Cycle 2 | — | 23348 ± 28 | 4323 ± 39 |
| Nivo Cycle 3 | 23147 ± 31 | — | — |
| Ipi Cycle 1 | 2847 ± 18 | 3377 ± 27 | 9893 ± 21 |
| Ipi Cycle 2 | — | 4959 ± 28 | 11388 ± 34 |
| Ipi Cycle 3 | 3480 ± 18 | — | — |
AUC(TAU) - Area under the concentration-time curve in one dosing interval in Part 1.
| h*ug/mL | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 1 | 10333 ± 21 | 13919 ± 26 | 4002 ± 19 |
| Nivo Cycle 2 | — | 24467 ± 23 | 4647 ± 48 |
| Nivo Cycle 3 | 28098 ± 18 | — | — |
| Ipi Cycle 1 | — | 3339 ± 27 | 9808 ± 17 |
| Ipi Cycle 2 | — | 5377 ± 20 | 12206 ± 36 |
Ceoinf - Serum concentration achieved at the end of study drug infusion in Part 1.
| ug/mL | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 1 | 59.4 ± 19 | 68.4 ± 21 | 22.5 ± 14 |
| Nivo Cycle 2 | — | 99.5 ± 15 | 25.4 ± 24 |
| Nivo Cycle 3 | 120 ± 21 | — | — |
| Ipi Cycle 1 | 17.7 ± 26 | 14.0 ± 50 | 54.8 ± 33 |
| Ipi Cycle 2 | — | 16.3 ± 39 | 62.7 ± 27 |
| Ipi Cycle 3 | 17.1 ± 33 | — | — |
Ctau - Concentration at the end of dosing interval in Part 1. The Ctau is equivilant to the CTrough at these time points.
| ug/mL | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 1 | 19.7 ± 24 | 16.0 ± 32 | 3.46 ± 32 |
| Nivo Cycle 2 | — | 40.6 ± 30 | 3.32 ± 70 |
| Nivo Cycle 3 | 63.2 ± 24 | — | — |
| Ipi Cycle 1 | 4.85 ± 25 | 3.22 ± 34 | 8.72 ± 33 |
| Ipi Cycle 2 | — | 6.74 ± 24 | 15.4 ± 27 |
| Ipi Cycle 3 | 6.07 ± 20 | — | — |
CLT - Total body clearance in Part 1.
| mL/h | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 2 | — | 8.56 ± 37 | 13.1 ± 51 |
| Nivo Cycle 3 | 6.99 ± 16 | — | — |
| Ipi Cycle 2 | — | 13.0 ± 36 | 15.0 ± 55 |
| Ipi Cycle 3 | NA ± NA | — | — |
Css-avg - Average concentration over a dosing interval (AUC(TAU)/tau) in Part 1.
| ug/mL | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 1 | 30.8 ± 21 | 27.6 ± 26 | 7.94 ± 19 |
| Nivo Cycle 2 | — | 48.5 ± 23 | 9.22 ± 48 |
| Nivo Cycle 3 | 83.6 ± 18 | — | — |
| Ipi Cycle 1 | — | 6.63 ± 27 | 19.5 ± 17 |
| Ipi Cycle 2 | — | 10.7 ± 20 | 24.2 ± 36 |
AI - Accumulation index; ratio of an exposure measure at steady-state to that after the first dose (exposure measure includes AUC (TAU) in Part 1. Here SS = Steady State Here FD = First Dose
| ratio of AUC(Tau) at SS vs FD | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 2 | — | 1.65 ± 22 | 1.13 ± 30 |
| Nivo Cycle 3 | 2.71 ± 4 | — | — |
| Ipi Cycle 2 | — | 1.50 ± 20 | 1.26 ± 22 |
| Ipi Cycle 3 | NA ± NA | — | — |
T-HALFeff - Effective elimination half-life that explains the degree of accumulation observed for a specific exposure measure (exposure measure includes AUC(TAU), Cmax, or Ctau) in Part 1.
| Hours | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Nivo Cycle 2 | — | 385 ± 36 | 263 ± 37 |
| Nivo Cycle 3 | 507 ± 4 | — | — |
| Ipi Cycle 2 | — | 325 ± 38 | 282 ± 14 |
| Ipi Cycle 3 | NA ± NA | — | — |
Number of participants with nivolumab Anti Drug Antibodies in Part 1.
| Participants | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Baseline ADA Positive | 0 | 2 | 0 |
| ADA Positive | 0 | 0 | 3 |
| Neutralizing Positive | 0 | 0 | 1 |
| ADA Negative | 9 | 9 | 4 |
Number of participants with Ipilimumab Anti Drug Antibodies in Part 1.
| Participants | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C |
|---|---|---|---|
| Baseline ADA Positive | 1 | 0 | 2 |
| ADA Positive | 0 | 0 | 0 |
| Neutralizing Positive | 0 | 0 | 0 |
| ADA Negative | 9 | 9 | 7 |
ORR is defined as the number of subjects with a best overall response (BOR) of confirmed complete response (CR) or partial response (PR) assessed by Investigator, according to RECIST v1.1 criteria, divided by the number of treated subjects. The BOR is defined as the best response designation recorded between the date of first dose and the date of initial objectively documented progression per RECIST v1.1 or the date of subsequent therapy, whichever occurs first. For participants without documented progression or subsequent therapy, all available response designations will contribute to the BOR determination. For purposes of analysis, if a subject receives one dose and discontinues the study without assessment or receives subsequent therapy prior to assessment, this participant will be counted in the denominator (as nonrespondent).
| Percentage of Participants | Part 2: Arm D |
|---|---|
| Investigator-Assessed ORR in Part 2 | 66.7 (29.9 to 92.5) |
The percentage of participants whose BOR is confirmed CR or confirmed PR or stable disease (SD) for at least 12 weeks as per investigator.
| Percentage of Participants | Part 2: Arm D |
|---|---|
| Investigator-Assessed Disease Control Rate (DCR) in Part 2 | 88.9 (51.8 to 99.7) |
The percentage of participants whose BOR is confirmed CR or confirmed PR or stable disease (SD) for at least 12 weeks as per BICR.
| Percentage of Participants | Part 2: Arm D |
|---|---|
| BICR-Assessed Disease Control Rate (DCR) in Part 2 | 88.9 (51.8 to 99.7) |
The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per BICR.
| Months | Part 2: Arm D |
|---|---|
| BICR-Assessed Duration of Response (DOR) in Part 2 | NA (15.21 to NA) |
The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per investigator.
| Months | Part 2: Arm D |
|---|---|
| Investigator-Assessed Duration of Response (DOR) in Part 2 | NA (NA to NA) |
The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per BICR.
| Months | Part 2: Arm D |
|---|---|
| BICR-Assessed Progression Free Survival (PFS) in Part 2 | NA (1.22 to NA) |
The time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first as per investigator.
| Months | Part 2: Arm D |
|---|---|
| Investigator-Assessed Progression Free Survival (PFS) in Part 2 | NA (1.22 to NA) |
Collected over All-Cause mortality, Adverse Events and Serious Adverse Events: From first dose to 100 days post last dose (Approximately on average Arm A: 8.77 Months, Arm B 20.4 Months, Arm C 24.1 Months and Arm D: 23.8 Months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1: Arm A | 2/9 (22.2%) | 4/9 (44.4%) | 7/9 (77.8%) |
| Part 1: Arm B | 2/9 (22.2%) | 3/9 (33.3%) | 9/9 (100%) |
| Part 1: Arm C | 1/9 (11.1%) | 3/9 (33.3%) | 9/9 (100%) |
| Part 2: Arm D | 1/9 (11.1%) | 4/9 (44.4%) | 9/9 (100%) |
| Event | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C | Part 2: Arm D |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/9 | 0/9 | 0/9 | 0/9 |
| Thyroiditis subacuteEndocrine disorders | 0/9 | 1/9 | 0/9 | 0/9 |
| PancreatitisGastrointestinal disorders | 0/9 | 0/9 | 0/9 | 1/9 |
| VomitingGastrointestinal disorders | 0/9 | 0/9 | 1/9 | 0/9 |
| Hepatic function abnormalHepatobiliary disorders | 0/9 | 1/9 | 0/9 | 1/9 |
| Liver injuryHepatobiliary disorders | 0/9 | 0/9 | 1/9 | 0/9 |
| CellulitisInfections and infestations | 0/9 | 1/9 | 0/9 | 0/9 |
| PneumoniaInfections and infestations | 0/9 | 0/9 | 1/9 | 0/9 |
| Alanine aminotransferase increasedInvestigations | 0/9 | 0/9 | 0/9 | 1/9 |
| MalnutritionMetabolism and nutrition disorders | 0/9 | 0/9 | 0/9 | 1/9 |
| Event | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C | Part 2: Arm D |
|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 4/9 | 6/9 | 2/9 | 3/9 |
| PyrexiaGeneral disorders | 5/9 | 2/9 | 6/9 | 2/9 |
| Aspartate aminotransferase increasedInvestigations | 1/9 | 3/9 | 4/9 | 6/9 |
| HypothyroidismEndocrine disorders | 1/9 | 3/9 | 3/9 | 5/9 |
| Alanine aminotransferase increasedInvestigations | 1/9 | 3/9 | 4/9 | 5/9 |
| PruritusSkin and subcutaneous tissue disorders | 1/9 | 3/9 | 5/9 | 2/9 |
| LeukopeniaBlood and lymphatic system disorders | 1/9 | 4/9 | 0/9 | 0/9 |
| HyperthyroidismEndocrine disorders | 0/9 | 1/9 | 4/9 | 1/9 |
| Blood bilirubin increasedInvestigations | 0/9 | 2/9 | 2/9 | 4/9 |
| Blood creatine phosphokinase increasedInvestigations | 0/9 | 3/9 | 4/9 | 1/9 |
| Age, Categorical(Participants) | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C | Part 2: Arm D | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 7 | 8 | 8 | 6 | 29 |
| >=65 years | 2 | 1 | 1 | 3 | 7 |
| Sex: Female, Male(Participants) | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C | Part 2: Arm D | Total |
|---|---|---|---|---|---|
| Female | 1 | 3 | 4 | 5 | 13 |
| Male | 8 | 6 | 5 | 4 | 23 |
| Ethnicity (NIH/OMB)(Participants) | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C | Part 2: Arm D | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 9 | 9 | 9 | 9 | 36 |
| Race (NIH/OMB)(Participants) | Part 1: Arm A | Part 1: Arm B | Part 1: Arm C | Part 2: Arm D | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 9 | 9 | 9 | 9 | 36 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Aug 2017 to primary completion in Jan 2024, 77 months.
Results were first posted in Sep 2025, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Nivolumab · Ipilimumab